210. 単心室症 Single Ventricle Clinical trials / Disease details
臨床試験数 : 51 / 薬物数 : 53 - (DrugBank : 22) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67
Showing 1 to 10 of 51 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05647213 (ClinicalTrials.gov) | February 3, 2023 | 30/11/2022 | Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease | Safety and Feasibility of Autologous Induced Pluripotent Stem Cells of Cardiac Lineage in Subjects With Congenital Heart Disease Safety and Feasibility of Autologous Induced Pluripotent Stem Cells of Cardiac Lineage in Subjects W ... | Univentricular Heart;Congenital Heart Disease;Heart Failure NYHA Class III;Heart Failure NYHA Class IV Univentricular Heart;Congenital Heart Disease;Heart Failure NYHA Class III;Heart Failure NYHA Class ... | Biological: iPSC-CL | HeartWorks, Inc. | NULL | Recruiting | 18 Years | 40 Years | All | 50 | Phase 1 | United States |
| 2 | NCT03997097 (ClinicalTrials.gov) | June 1, 2022 | 18/6/2019 | Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Dis ... | Phosphodiesterase-type 5 Inhibitors in Adult and Adolescent Patients With Univentricular Heart Disease: a Multi-center, Randomized, Double Blind Phase III Study Phosphodiesterase-type 5 Inhibitors in Adult and Adolescent Patients With Univentricular HeartDiseas ... | Single-ventricle;Pulmonary Hypertension;Univentricular Heart | Drug: Sildenafil;Drug: Placebos | University Hospital, Montpellier | NULL | Not yet recruiting | 15 Years | 80 Years | All | 50 | Phase 3 | NULL |
| 3 | NCT04901975 (ClinicalTrials.gov) | February 11, 2021 | 14/5/2021 | Fibrosis and the Fontan | Acute Imposition of Fontan Physiology in The Single Ventricle Patient: Effects on Fibrosis, Function and Drug Intervention Acute Imposition of Fontan Physiology in The Single VentriclePatient: Effects on Fibrosis, Function ... | Single-ventricle | Drug: Spironolactone | Children's Hospital of Philadelphia | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 1 Year | 6 Years | All | 120 | Phase 1/Phase 2 | United States |
| 4 | NCT04292483 (ClinicalTrials.gov) | June 11, 2020 | 29/2/2020 | Pulmonary Capillary Recruitment in Fontan Patients | Pulmonary Capillary Recruitment With Pulmonary Vasodilator Therapy in Patients With Univentricular Heart Physiology and Failing Total Cavo-pulmonary Connection. Pulmonary Capillary Recruitment With Pulmonary Vasodilator Therapy in Patients With Univentricular H ... | Congenital Heart Disease | Drug: Nitric Oxide | Jewish General Hospital | National and Kapodistrian University of Athens;Tel Aviv University;Old Dominion University | Recruiting | 18 Years | 60 Years | All | 15 | Canada | |
| 5 | EUCTR2018-002821-45-CZ (EUCTR) | 29/04/2020 | 23/03/2020 | An upcoming clinical study to measure the safety and impact of a drug called macitentan in teenage and adult Fontan patients An upcoming clinical study to measure the safety and impact of a drug called macitentan in teenage a ... | AC-055H302, RUBATO OL, Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability, and effectiveness of macitentan in Fontan-palliated adult and adolescent subjects - RUBATO OL AC-055H302, RUBATO OL, Prospective, multi-center, single-arm, open-label long-term study assessing t ... | Congenital Heart Failure MedDRA version: 20.0;Level: PT;Classification code 10045545;Term: Univentricular heart;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.1;Classification code 10065950;Term: Cavopulmonary anastomosis;System Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] Congenital Heart Failure MedDRA version: 20.0;Level: PT;Classification code 10045545;Term: Univentri ... | Trade Name: Opsumit® Product Name: macitentan Product Code: ACT-064992 INN or Proposed INN: MACITENTAN | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 134 | Phase 3 | United States;France;Taiwan;Czech Republic;Poland;Ireland;Denmark;Australia;Germany;United Kingdom;New Zealand;China United States;France;Taiwan;Czech Republic;Poland;Ireland;Denmark;Australia;Germany;United Kingdom;N ... | ||
| 6 | NCT03877965 (ClinicalTrials.gov) | August 5, 2019 | 14/3/2019 | Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease Pharmacokinetics and Safety Profile of Digoxin in Infants With Single VentricleCongenital Heart Dise ... | Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease Pharmacokinetics and Safety Profile of Digoxin in Infants With Single VentricleCongenital Heart Dise ... | Congenital Heart Disease | Drug: Digoxin | Christoph P Hornik, MD MPH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);The Emmes Company, LLC Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);The Emmes Co ... | Completed | N/A | 6 Months | All | 50 | United States | |
| 7 | EUCTR2018-002821-45-FR (EUCTR) | 05/03/2019 | 03/10/2018 | An upcoming clinical study to measure the safety and impact of a drug called macitentan in teenage and adult Fontan patients An upcoming clinical study to measure the safety and impact of a drug called macitentan in teenage a ... | Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability, and effectiveness of macitentan in Fontan-palliated adult and adolescent subjects - RUBATO OL Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability ... | Congenital Heart Failure MedDRA version: 20.0;Level: PT;Classification code 10045545;Term: Univentricular heart;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10065950;Term: Cavopulmonary anastomosis;System Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] Congenital Heart Failure MedDRA version: 20.0;Level: PT;Classification code 10045545;Term: Univentri ... | Trade Name: Opsumit® Product Name: macitentan Product Code: ACT-064992 INN or Proposed INN: MACITENTAN | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 134 | Phase 3 | United States;France;Taiwan;Czech Republic;Poland;Ireland;Denmark;Australia;Germany;United Kingdom;New Zealand;China United States;France;Taiwan;Czech Republic;Poland;Ireland;Denmark;Australia;Germany;United Kingdom;N ... | ||
| 8 | EUCTR2018-002821-45-DK (EUCTR) | 27/02/2019 | 02/01/2019 | An upcoming clinical study to measure the safety and impact of a drug called macitentan in teenage and adult Fontan patients An upcoming clinical study to measure the safety and impact of a drug called macitentan in teenage a ... | AC-055H302, RUBATO OL, Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability, and effectiveness of macitentan in Fontan-palliated adult and adolescent subjects - RUBATO OL AC-055H302, RUBATO OL, Prospective, multi-center, single-arm, open-label long-term study assessing t ... | Congenital Heart Failure MedDRA version: 20.0;Level: PT;Classification code 10045545;Term: Univentricular heart;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 21.1;Classification code 10065950;Term: Cavopulmonary anastomosis;System Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] Congenital Heart Failure MedDRA version: 20.0;Level: PT;Classification code 10045545;Term: Univentri ... | Trade Name: Opsumit® Product Name: macitentan Product Code: ACT-064992 INN or Proposed INN: MACITENTAN | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 134 | Phase 3 | United States;Czechia;Taiwan;Ireland;United Kingdom;France;Czech Republic;Poland;Denmark;Australia;Germany;China;New Zealand United States;Czechia;Taiwan;Ireland;United Kingdom;France;Czech Republic;Poland;Denmark;Australia;G ... | ||
| 9 | NCT03575572 (ClinicalTrials.gov) | August 29, 2018 | 18/6/2018 | Colchicine in Postoperative Fontan Patients | Colchicine in Postoperative Fontan Patients (CPFP) | Single-ventricle;Heart Diseases | Drug: Colchicine | University of Michigan | NULL | Terminated | 20 Months | 5 Years | All | 11 | Phase 2/Phase 3 | United States |
| 10 | NCT03430583 (ClinicalTrials.gov) | February 20, 2018 | 22/1/2018 | Evaluation of Fontan-Associated Liver Disease | Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Ex ... | Single Ventricle Heart Disease | Drug: MZ101 | Mezzion Pharma Co. Ltd | National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting | 12 Years | N/A | All | 100 | United States;Canada |